Koers Cellectar Biosciences Inc Nasdaq
Aandelen
US15117F3029
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | 44,27 mln. 41,12 mln. | Marktkapitalisatie | 110 mln. 102 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -49 mln. -45,51 mln. | Nettowinst (verlies) 2025 * | -22 mln. -20,43 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 2,49 x |
K/w-verhouding 2024 * |
-1,88
x | K/w-verhouding 2025 * |
-5,32
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,19% |
Recentste transcriptie over Cellectar Biosciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 15-06-15 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 28-05-14 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 07-04-17 |
Douglas Swirsky
CHM | Chairman | 54 | 07-04-17 |
John Neis
BRD | Director/Board Member | 68 | 01-02-08 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+30,38% | 684 mld. | |
+26,51% | 568 mld. | |
-4,36% | 361 mld. | |
+19,30% | 329 mld. | |
+3,73% | 284 mld. | |
+16,70% | 240 mld. | |
+8,78% | 208 mld. | |
-7,93% | 200 mld. | |
+7,68% | 166 mld. |